Evidence | Page 174 of 200 | SpiritIndia.com

Hypertension :: Results of TROPHY study on hypertension are misleading

There may be as many as 70 million Americans with prehypertension. If these people can be treated pharmacologically to avoid or delay progression to clinical hypertension, there would be significant benefits to them and the overall health of the population. The recent TROPHY study seems to lead to that conclusion. However, two editorials published in the November issue of the American Journal of Hypertension emphatically argue that the study is flawed and the conclusions reached are misleading.

Breastfeeding :: Breast milk boosts mental health in kids n babies

A new study has found that babies that are breastfed for longer than six months have significantly better mental health in childhood. The findings are based on data from the ground-breaking Raine Study at the Telethon Institute for Child Health Research, that has tracked the growth and development of more than 2500 West Australian children over the past 16 years.

Schizophrenia :: Neurophysiological link between cannabis use and schizophrenia

Researchers have found altered neural synchronization in people who smoke cannabis, providing evidence to support the link between the use of this drug and schizophrenia.

Heart Disease :: Two drinks daily help men avoid heart attack

Even healthy men may benefit from a drink or two daily to help lower the risk of heart attack, that can be like other lifestyle interventions such as regular physical activity, weight loss and quitting smoking.

Mumps :: Mumps activity in US highlights vaccine importance

In the wake of growing number of mumps cases in the US, the American medical authorities have updated their vaccination recommendations & asked for utilizing every opportunity to provide immunization to high-risk populations.

Breast Cancer :: Chemo drugs for treating breast cancer may cause changes in cognitive function

A new study investigating the effects of chemotherapy on cognitive function in mice has confirmed what many cancer patients receiving treatment have often complained about ? a decline in their memory and other cognitive functions, sometimes characterized as “chemobrain”.

Stroke :: AstraZeneca – SAINT II Trial Results Showed No Efficacy in Acute Ischaemic Stroke

Results from the SAINT II (Stroke Acute Ischemic NXY-059 Treatment) trial, announced today by AstraZeneca, showed that the investigational drug NXY-059 did not meet its primary outcome of a statistically significant reduction in stroke-related disability, as assessed by the modified Rankin Scale (mRS) (p=0.33, odds ratio 0.94) compared to placebo.

Psychiatry :: First Mani Bhaumik Award to UW Scientist for Insights into Brain’s Neuroplasticity

The Cousins Center for Psychoneuroimmunology at UCLA has named University of Wisconsin’s Richard Davidson as the first recipient of The Mani Bhaumik Award. The award was established earlier this year to support scientists in the international community who advance the understanding of the brain and the conscious mind in healing through visionary research, books and education. Bhaumik, co-inventor of the laser technology that made LASIK surgery possible, has funded the annual $10,000 award.

Ulcerative Colitis :: Adherence to ulcerative colitis medications is not affected by drug formulation or dosing regimen

Poor adherence to medication is a recognized medical problem, costing an estimated $100 billion a year in the United States.(i) New data show that while there is a steady decline in adherence to medications for ulcerative colitis (UC), drug formulation and the number of pills taken each day do not affect long-term adherence. The data were presented today at the annual scientific meeting of the American College of Gastroenterology by University of Chicago researcher Sunanda Kane, M.D.

Hepatitis :: Tyzeka, Sebivo or telbivudine for patients with chronic hepatitis B – Novartis

Novartis announced the US regulatory approval of Tyzeka(TM) (telbivudine) as a new once-a-day oral treatment for patients with chronic hepatitis B, a disease estimated to affect about 1.25 million people in the US but more than 350 million globally and considered the tenth leading cause of death.